Verzenios ® (abemaciklib)

För fullständig produktresumé för Verzenios se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

VERZENIOS® ▼ (abemaciclib): Verkningsmekanism

VERZENIOS (abemaciclib) har inte jämförts med andra CDK4- och 6-hämmare i kliniska prövningar.

Detailed Information

Abemaciclib is an inhibitor of CDK 4 and CDK 6 and was most active against cyclin D1/CDK 4 in enzymatic assays. In  breast cancer, cyclin D1/CDK 4  has been shown to promote phosphorylation of the Rb, cell proliferation, and tumor growth. Abemaciclib prevents Rb phosphorylation, blocking progression from G1 into S phase of the cell cycle, leading to suppression of tumor growth in preclinical models following short duration target inhibition. In ER+ breast cancer cell lines, sustained target inhibition by abemaciclib prevents rebound of Rb phosphorylation and cell cycle reentry, resulting in senescence and apoptosis. In breast cancer xenograft models, abemaciclib dosed daily without interruption at clinically relevant concentrations, as a single agent or in combination with antiestrogens, resulted in reduction of tumor size.1

For information on other CDK 4 and 6 inhibitors in this class, please contact the individual manufacturers of these drugs.

References

1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

CDK = cyclin-dependent kinase

ER+ = estrogen receptor-positive

Rb = retinoblastoma protein

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Datum fӧr senaste ӧversyn 2020 M01 21


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss